# OnCo record paper-symmans-rcb-long-term-prognosis-subtype-jco-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:ScholarlyArticle ;
onco:kind "paper" ;
schema:identifier "paper-symmans-rcb-long-term-prognosis-subtype-jco-2017" ;
schema:name "Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype"@en ;
schema:description "The 2017 validation of the residual cancer burden score, which graded how much triple-negative tumour is left after pre-surgery chemotherapy and found ten-year relapse-free survival of 86 percent with no residual tumour, 81 percent with minimal, 55 percent with moderate and 23 percent with extensive residual disease."@en ;
schema:url ;
schema:dateModified "2026-09-24"^^xsd:date ;
schema:citation , ;
onco:tag "tnbc-evidence" ;
schema:sameAs ;
schema:datePublished "2017"^^xsd:gYear ;
schema:author "Symmans WF, Wei C, Gould R, et al." ;
onco:related , ;
onco:cancers , , ;
onco:institutions ;
onco:terms , , ;
onco:trials , ;
onco:journals .